Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas

Rheumatology

Volumn 43, Issue 8, 2004, Pages 1050-1053

  Voulgarelis, M ^a   Giannouli, S ^a   Anagnostou, D ^a   Tzioufas, A G ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Cryoglobulinaemia; Lymphoma; Rituximab; Sj gren's syndrome

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; COMPLEMENT COMPONENT C4; CRYOGLOBULIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; PREDNISONE; RHEUMATOID FACTOR; RITUXIMAB; STEROID; VINCRISTINE; CHOP PROTOCOL; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTHRALGIA; ARTICLE; B CELL LYMPHOMA; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CASE REPORT; CENTRAL NERVOUS SYSTEM DISEASE; CHILL; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYOGLOBULINEMIA; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEVER; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; NEUROTOXICITY; NONHODGKIN LYMPHOMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PURPURA; SJOEGREN SYNDROME; SYMPTOMATOLOGY; B LYMPHOCYTE; DRUG COMBINATION; IMMUNOLOGY; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B-LYMPHOCYTES; CRYOGLOBULINEMIA; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG THERAPY, COMBINATION; HUMANS; LYMPHOMA, B-CELL; MIDDLE AGED; PREDNISONE; SJOGREN'S SYNDROME; TREATMENT OUTCOME; VINCRISTINE;

EID: 4344600949     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keh248     Document Type: Article

References (18)

1. Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM. Malignant lymphoma in primary Sjogren's syndrome. Arthritis Rheum 1999;42:1765-72.
2. Fisher RI, Gaynor FR, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-6.
3. Mournier N, Briere J, Gisselbrecht C et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2 associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003;101:4279-84.
4. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42.
5. Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group, Blood 1994;84:1361-92.
6. Karnofsky DA, Abelmann WH, Graver LF, Buekenal JH. The use of nitrogen mustards in the palliative treatment of cancer. Cancer 1948;1:634-56.
7. Vitali C, Bombardieri S, Jonsson R et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
8. Carbone PP, Kaplan HS, Musshoff K, Struthers DW, Tubiana M. Report on the Committee on Hodgkin's disease staging classification. Cancer Res 1971;31:1860-1.
9. Shipp MA, Harrington DP, Anderson JR et al. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987-94.
10. Skopouli FN, Dafni U, Ioannidis JPA, Moutsopoulos HM. Clinical evolution, and morbidity and mortality of primary Sjogren's syndrome. Semin Arthritis Rheum 2000;29:296-304.
11. Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren's syndrome. Arthritis Rheum 2002;46:741-7.
12. Peng H, Du M, Diss TC, Isaacson PG, Pan L. Genetic evidence for a clonal link between low and high-grade components in gastric MALT B-cell lymphoma. Histopathology 1997;30:425-9.
13. Raderer M, Jager G, Brugger S et al. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma tissue lymphoma. Oncology 2003;65:306-10.
14. Tilly H, Lepage E, Coiffier B et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2003; 102:4284-9.
15. Martin T, Weber JC, Levallois H et al. Salivary gland lymphomas in patients with Sjogren's syndrome may frequent develop from rheumatoid factors B cells. Arthritis Rheum 2000;43:908-16.
16. Zaja F, DeVita S, Mazzaro C et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003;101:3827-34.
17. Treon SP, Anderson KC. The use of rituximab in the treatment of malignant and non-malignant plasma cell disorders. Semin Oncol 2000;27(Suppl. 12):79-85.
18. Manz RA, Arce S, Cassese G, Hauser AE, Hiepe F, Radbruch A. Humoral immunity and long-lived plasma cells. Curr Opin Immunol 2002;17:517-21.